Clinical Trials - March 31, 2022
TILT Biotherapeutics reports Phase I results
TILT Biotherapeutics has announced positive interim progress and safety data from its phase 1 clinical trials in metastatic melanoma (T215 – the ‘TUNINTIL’ trial) and solid tumors (T115 – the ‘TUNIMO’ trial). These two trials, with patients in Denmark, France, and Finland, are of the company’s oncolytic immunotherapy asset TILT-123, designed to stimulate T-cells to […]
Drug Development Pharma - August 27, 2021
TILT Biotherapeutics announces publication of pre-clinical data
New preclinical data relating to the use of the company’s oncolytic immunotherapy platform for expressing a human IL-2 variant protein has been published in Frontiers in Immunology. The paper was independently authored by researchers at the University of Helsinki and other leading institutions, together with TILT Biotherapeutics. TILT-452 The paper describes a study with TILT-452, […]
Clinical Trials - June 15, 2021
TILT Biotherapeutics submits IND application
TILT Biotherapeutics has submitted an IND for its Phase I trial of immunotherapeutic TILT-123 in ovarian cancer. The trial will evaluate the company’s adenoviral cancer immunotherapy TILT-123, a double cytokine armed oncolytic adenovirus, in combination with KEYTRUDA (pembrolizumab), MSD’s anti-PD-1 therapy, in a dose escalation trial in platinum resistant or refractory ovarian cancer patients. About […]
Clinical Trials - May 5, 2021
First patient dosed in TILT Biotherapeutics’ Phase I trial
The company has progressed to the second dose level in a monotherapy phase 1 clinical trial of TILT-123, a dual cytokine armed oncolytic adenovirus. The trial is being performed in patients with injectable solid tumors. Patients are being treated at Docrates Cancer Center and Helsinki University Hospital. “We expect the trial to provide valuable data […]
